CD44 and hepatocellular carcinoma: Around the same time, a similar finding was obtained from a study by Chou et al.[14], which found that CD44 rs187115 polymorphism may serve as a biomarker for predicting prognosis of late-stage hepatocellular carcinoma (HCC).